Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism.
Turgeon
Jacques
J
Faculté de pharmacie, Université de Montréal, Montréal, Que. jacques.turgeon@umontreal.ca
Pharand
Chantal
C
Michaud
Véronique
V
D000077144:Clopidogrel; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D004347:Drug Interactions; D017700:Embolism, Cholesterol / Q000139:chemically induced*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D011110:Polymorphism, Genetic; D012307:Risk Factors; D013927:Thrombosis / Q000139:chemically induced*; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives*
D010975:Platelet Aggregation Inhibitors; D003577:Cytochrome P-450 Enzyme System; D000077144:Clopidogrel; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; D013988:Ticlopidine